Analysts are on the Bearish side about Pacific Biosciences of California, Inc. (NASDAQ:PACB) this week.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) LogoInvestors sentiment decreased to 1.34 in 2018 Q2. Its down 0.59, from 1.93 in 2018Q1. It worsened, as 11 investors sold Pacific Biosciences of California, Inc. shares while 21 reduced holdings. 10 funds opened positions while 33 raised stakes. 85.41 million shares or 3.21% less from 88.24 million shares in 2018Q1 were reported.
Moreover, Bridgeway Cap Inc has 0.01% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Jpmorgan Chase Co holds 24,740 shares or 0% of its portfolio. Citadel Ltd Company owns 650,668 shares. Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 2,957 shares. Bnp Paribas Arbitrage holds 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB) or 4,249 shares. Great West Life Assurance Can holds 9,087 shares or 0% of its portfolio. Schwab Charles Investment Mngmt reported 614,288 shares. Ameriprise Fincl holds 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB) or 15,992 shares. Bancorp Of America De reported 16,557 shares. Moreover, Frontier Management Com Limited Liability Corp has 0.04% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 1.43 million shares. United Services Automobile Association accumulated 17,021 shares. Moreover, State Board Of Administration Of Florida Retirement has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB). holds 0.01% in Pacific Biosciences of California, Inc. (NASDAQ:PACB) or 9.38M shares. 3,936 were accumulated by Royal Bancshares Of Canada. Invesco reported 17,979 shares.

Since November 27, 2018, it had 0 insider purchases, and 1 insider sale for $188,500 activity.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Ratings Coverage

Among 2 analysts covering Pacific Biosciences (NASDAQ:PACB), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Pacific Biosciences had 3 analyst reports since August 9, 2018 according to SRatingsIntel. The stock of Pacific Biosciences of California, Inc. (NASDAQ:PACB) earned “Neutral” rating by Cantor Fitzgerald on Monday, November 12. Below is a list of Pacific Biosciences of California, Inc. (NASDAQ:PACB) latest ratings and price target changes.

12/11/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
19/10/2018 Broker: Cowen & Co Rating: Outperform New Target: $6.5 Initiates Coverage On
09/08/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $5 Initiates Coverage On

The stock increased 2.89% or $0.22 during the last trading session, reaching $7.82. About 4.59M shares traded or 18.20% up from the average. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has declined 10.66% since December 1, 2017 and is downtrending. It has underperformed by 26.28% the S&P500.

Pacific Biosciences of California, Inc. designs, develops, and makes sequencing systems to resolve genetically complex problems. The company has market cap of $1.16 billion. The companyÂ’s single molecule real-time sequencing technology enables single molecule real-time detection of biological processes. It currently has negative earnings. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions.

More notable recent Pacific Biosciences of California, Inc. (NASDAQ:PACB) news were published by: Benzinga.com which released: “34 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on November 02, 2018, also Benzinga.com with their article: “Illumina Buys Rival Pacific Biosciences In $1.2B Deal (NASDAQ:PACB)(NASDAQ:ILMN) – Benzinga” published on November 02, 2018, Nasdaq.com published: “Pacific Biosciences (PACB) Up 73.4% Since Last Earnings Report: Can It Continue? – Nasdaq” on December 01, 2018. More interesting news about Pacific Biosciences of California, Inc. (NASDAQ:PACB) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Mostly Higher; Apple Issues Weak Sales Forecast – Nasdaq” published on November 02, 2018 as well as Seekingalpha.com‘s news article titled: “Healthcare and Tech top list of midday movers (11/02/2018) – Seeking Alpha” with publication date: November 02, 2018.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.